El Gantery 2014.

Study characteristics
Methods	Single institution, RCT Intention‐to‐treat analysis
Participants	This study randomized participants into 3 arms, 21 participants received WBRT, 18 participants received SRS, and 21 participants received WBRT plus SRS Inclusion criteria: patients with MRI‐confirmed 1‐3 brain metastases with a maximum diameter < 4 cm derived from a histologically confirmed systemic cancer. Age < 70 years, KPS > 70%, ensured adequate organ function, no previous treatment for brain metastases Exclusion criteria: Age > 70, KPS < 70%
Interventions	The WBRT dosage schedule was 30 Gy in 10 fractions over 2 weeks The prescribed dose of SRS in the WBRT plus SRS arm ranged from 14 to 20 Gy (mean = 14.6 Gy, median = 14 Gy)
Outcomes	Median OS, local control, and adverse events
Notes	Steroid requirement, functional status, and quality of life were not assessed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants in each of the three treatment arms were analyzed
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgment
Other bias	High risk	Small sample sizes in each treatment arm